Rozanolixizumab (Rystiggo, UCB) is indicated 'as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive'.
The dosage schedule is available in the summary of product characteristics for rozanolixizumab.
The list price of rozanolixizumab is £17,883.19 per 560 mg/4 ml vial of solution for injection (excluding VAT; BNF online accessed April 2026).
The company has a commercial arrangement. This makes rozanolixizumab available to the NHS with a discount. The size of the discount is commercial in confidence.
For information, the Carbon Reduction Plan for UK carbon emissions is published on UCB's webpage on sustainability.